The use of ondansetron for the treatment of nausea in dogs with vestibular syndrome.
Behavioural Assessment
Nausea
Ondansetron
Vestibular syndrome
Journal
BMC veterinary research
ISSN: 1746-6148
Titre abrégé: BMC Vet Res
Pays: England
ID NLM: 101249759
Informations de publication
Date de publication:
21 Jun 2021
21 Jun 2021
Historique:
received:
26
02
2021
accepted:
07
06
2021
entrez:
22
6
2021
pubmed:
23
6
2021
medline:
15
10
2021
Statut:
epublish
Résumé
Vestibular syndrome is often accompanied by nausea. Drugs currently approved for its treatment have been developed to stop vomiting but not nausea. The efficacy of 5-HT Sixteen dogs with vestibular syndrome-associated nausea were included in the open-label, multicentre study. The intensity of nausea-like behaviour was analysed before ondansetron administration (0.5 mg/kg i.v.) and 2 h afterwards, using a validated 5-point-scale. The occurrence and frequency of salivation, lip licking, restlessness, vocalisation, lethargy, and vomiting were assessed. All dogs initially showed signs of nausea, whereas only 31% showed vomitus. The intensity of nausea was significantly reduced in all dogs (p ≤ 0.0001) 2 h after ondansetron administration, including the clinical signs of nausea analysed in 11 dogs (salivation [p = 0.0078], lip licking [p = 0.0078], restlessness [p = 0.0039], and lethargy [p = 0.0078]) except for vocalisation (p > 0.9999). The results provide preliminary evidence of the potential benefit of ondansetron in the treatment of nausea, which was present in all examined dogs. Vomiting was only observed in 5 dogs indicating that nausea can occur separately and should not be perceived only as a preceding stimulation of the vomiting centre.
Sections du résumé
BACKGROUND
BACKGROUND
Vestibular syndrome is often accompanied by nausea. Drugs currently approved for its treatment have been developed to stop vomiting but not nausea. The efficacy of 5-HT
METHODS
METHODS
Sixteen dogs with vestibular syndrome-associated nausea were included in the open-label, multicentre study. The intensity of nausea-like behaviour was analysed before ondansetron administration (0.5 mg/kg i.v.) and 2 h afterwards, using a validated 5-point-scale. The occurrence and frequency of salivation, lip licking, restlessness, vocalisation, lethargy, and vomiting were assessed.
RESULTS
RESULTS
All dogs initially showed signs of nausea, whereas only 31% showed vomitus. The intensity of nausea was significantly reduced in all dogs (p ≤ 0.0001) 2 h after ondansetron administration, including the clinical signs of nausea analysed in 11 dogs (salivation [p = 0.0078], lip licking [p = 0.0078], restlessness [p = 0.0039], and lethargy [p = 0.0078]) except for vocalisation (p > 0.9999).
CONCLUSIONS
CONCLUSIONS
The results provide preliminary evidence of the potential benefit of ondansetron in the treatment of nausea, which was present in all examined dogs. Vomiting was only observed in 5 dogs indicating that nausea can occur separately and should not be perceived only as a preceding stimulation of the vomiting centre.
Identifiants
pubmed: 34154584
doi: 10.1186/s12917-021-02931-9
pii: 10.1186/s12917-021-02931-9
pmc: PMC8218477
doi:
Substances chimiques
Antiemetics
0
Ondansetron
4AF302ESOS
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
222Références
Am J Vet Res. 2007 Jan;68(1):48-56
pubmed: 17199418
Can Vet J. 2017 Jan;58(1):35-38
pubmed: 28042152
J Am Vet Med Assoc. 2001 Feb 1;218(3):385-91
pubmed: 11201565
Ann N Y Acad Sci. 1996 Jun 19;781:670-2
pubmed: 8694472
Therap Adv Gastroenterol. 2016 Jan;9(1):98-112
pubmed: 26770271
Vet J. 2015 Jan;203(1):36-43
pubmed: 25453240
Am J Physiol. 1997 Apr;272(4 Pt 1):G853-62
pubmed: 9142918
Vet Rec. 2007 Sep 29;161(13):444-7
pubmed: 17906225
Support Care Cancer. 2002 Mar;10(2):96-105
pubmed: 11862499
Vet J. 2018 Jun;236:72-79
pubmed: 29871754
Neurogastroenterol Motil. 1997 Sep;9(3):141-2
pubmed: 9347468
BMC Vet Res. 2017 Jul 5;13(1):212
pubmed: 28676057
J Vet Intern Med. 2014 Sep-Oct;28(5):1414-7
pubmed: 25146756
J Physiol. 2015 Mar 1;593(5):1183-96
pubmed: 25557265
Vet Clin North Am Small Anim Pract. 2010 Jan;40(1):81-100
pubmed: 19942058
Top Companion Anim Med. 2014 Mar;29(1):6-9
pubmed: 25103883
Iran J Cancer Prev. 2015 Mar-Apr;8(2):84-8
pubmed: 25960846
Acad Emerg Med. 2009 Dec;16(12):1304-1310
pubmed: 20053251
Open Access Maced J Med Sci. 2018 Oct 18;6(10):1833-1838
pubmed: 30455758
J Comp Neurol. 1998 Dec 21;402(3):385-401
pubmed: 9853906
Neurosci Lett. 1988 Nov 22;94(1-2):156-60
pubmed: 3241663
J Small Anim Pract. 2010 Jan;51(1):4-22
pubmed: 20137004
Acta Otolaryngol Suppl. 2004 Aug;(553):50-3
pubmed: 15277036
J Vet Pharmacol Ther. 2014 Aug;37(4):348-53
pubmed: 24330064
Brain Res. 1994 Feb 21;637(1-2):222-6
pubmed: 8180799
Eur J Pharmacol. 1989 Dec 12;174(1):127-30
pubmed: 2612576
Clin Endocrinol (Oxf). 1990 Dec;33(6):761-70
pubmed: 1982863
Vet J. 2010 Sep;185(3):247-58
pubmed: 19944632
J Small Anim Pract. 2020 Jan;61(1):57-63
pubmed: 31515806
J Neurol. 2000 Jul;247(7):491-9
pubmed: 10993488
BMC Vet Res. 2017 Aug 16;13(1):244
pubmed: 28814338
J Am Vet Med Assoc. 2014 Apr 1;244(7):820-9
pubmed: 24649993
J Am Vet Med Assoc. 2018 Apr 1;252(7):830-838
pubmed: 29553894
Arch Toxicol. 2011 Dec;85(12):1565-73
pubmed: 21626407
Am Fam Physician. 2004 Mar 1;69(5):1169-74
pubmed: 15023018
J Small Anim Pract. 2006 Oct;47(10):582-7
pubmed: 17004950
Eur J Pharmacol. 1993 Sep 7;241(1):47-54
pubmed: 8223924
Am J Physiol. 1994 Oct;267(4 Pt 2):R974-83
pubmed: 7524372
J Vet Intern Med. 2010 Nov-Dec;24(6):1452-7
pubmed: 21039869
CNS Drug Rev. 2001 Summer;7(2):199-213
pubmed: 11474424
Proc Natl Acad Sci U S A. 1993 Feb 15;90(4):1430-4
pubmed: 8434003
Ann Rheum Dis. 1978 Aug;37(4):378-81
pubmed: 686873
Vet Clin North Am Small Anim Pract. 1988 May;18(3):641-65
pubmed: 3289249
J Small Anim Pract. 1998 Oct;39(10):469-74
pubmed: 9816569
Drug Discov Today Ther Strateg. 2007;4(3):183-187
pubmed: 19081819
PLoS One. 2014 Jan 23;9(1):e86730
pubmed: 24466215
Eur J Pharmacol. 2014 Jan 5;722:108-21
pubmed: 24157981
Br J Cancer Suppl. 1992 Dec;19:S2-7; discussion S7-8
pubmed: 1467196
Vet Anaesth Analg. 2017 Jul;44(4):785-793
pubmed: 28844293
Neuropharmacology. 1986 Jun;25(6):563-76
pubmed: 2875415
BMC Vet Res. 2020 May 25;16(1):159
pubmed: 32450859
Front Vet Sci. 2019 Aug 22;6:264
pubmed: 31508429
Trends Pharmacol Sci. 1990 Apr;11(4):135-7
pubmed: 2333665
Ochsner J. 2009 Spring;9(1):20-6
pubmed: 21603405
J Vet Intern Med. 2020 Sep;34(5):1993-2004
pubmed: 32776616
Eur J Oncol Nurs. 2005 Mar;9(1):21-32
pubmed: 15774338